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expression and reverse IgA dys-glycosylation in
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Background: Decreased Core I β3-Gal-T-specific molecular chaperone (Cosmc) expression induced IgA1 aberrant
glycosylation is the main characteristic of IgA nephropathy (IgAN). This study tried to elucidate the effect of Astragalus
membranaceus on Cosmc expression and IgA O-glycosylation of peripheral B lymphocytes in IgAN patients.
Methods: Peripheral B lymphocytes of 21 IgAN patients and 10 normal controls were isolated and cultured with
or without lipopolysaccharide (LPS) and Astragalus membranaceus injection (AMI). Cosmc mRNA and protein expression
levels were measured by real-time RT-PCR and Western blot. IgA1 and glycosylation level were determined by
enzyme-linked immunosorbent assay (ELISA) and VV lectin-binding method.
Results: Cosmc mRNA expression and IgA1 O-glycosylation level in IgAN patients was significantly lower than normal
controls at baseline. Treatment of LPS could obviously inhibit Cosmc expression and increase the IgA1 secretion in
peripheral B lymphocytes of IgAN patients, which resulted in a significantly increase in IgA1 aberrant glycosylation level.
Addition of AMI could remarkably up regulated Cosmc expression, decrease IgA1 secretion, and reverse glycosylation
level in a dose related manner.
Conclusion: AMI can up-regulate Cosmc expression of peripheral B lymphocytes and reverse IgA1 aberrant
O-glycosylation level, which might be the underlying mechanism of AMI therapy in treating IgAN.
Trial registration: TCTR20140515001 (Registration Date: 2014-05-15)
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IgA nephropathy (IgAN) is one of the most common
glomerulonephritis in the world, accounts for >50%
of biopsy-proven primary glomerulonephritis in Asia,
especially in China [1,2]. Recent investigations indicated
that abnormalities of IgA1 O-glycosylation induced by
decreased Cosmc (core I β3-Gal-T-specific molecular
chaperone) expression may be one of the key pathogeneses
of IgAN [3]. Reversing of Cosmc expression and aberrant
IgA1 O-glycosylation may be a potential treatment
of IgAN.* Correspondence: ddqstrike@163.com
†Equal contributors
1Division of Nephrology, Department of Medicine, West China Hospital of
Sichuan University, 37 # Guoxue road, Wuhou District, Chengdu, Sichuan,
China
Full list of author information is available at the end of the article
© 2014 Ji et al.; licensee BioMed Central Ltd. T
Commons Attribution License (http://creativec
reproduction in any medium, provided the orAstragalus membranaceus (AM) is a traditional Chinese
herb, which is widely used in treating various renal diseases,
including IgAN [4,5]. Many studies demonstrated to
that AM have therapeutic effects on reducing proteinuria,
reversing hyperlipidaemia, regulating auto-immunity and
protecting kidney function in vitro and in vivo. However,
the underlying molecular mechanism of its effect in treating
IgAN is far from clear. In the present study we aimed
to elucidate whether the up-regulation of Cosmc
expression and reversing of IgA1 dys-glycosylation are
underlying mechanisms of therapeutic action of Astragalus
membranaceus in IgAN.Methods
Patients and normal controls
Twenty-one biopsy-proven IgAN patients were included
in this study. Diagnosis of IgAN was based on thehis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.





Table 2 Baseline clinical characters of IgAN patients
IgAN (n = 21) Control (n = 10)
Age (years) 27.53 ± 9.38* 29.5 ± 4.2*
Males/females 11/10 6/4
Disease duration (months) 14.12 ± 23.28* N/A
Blood Pressure systolic (mmHg) 117.6 ± 15.8* 108.5 ± 15.5*
Blood Pressure diastolic (mmHg) 75.5 ± 11.6* 65.5 ± 6.8*
Proteinuria (g/24 hr) 2.8 ± 1.7 N/A
Serum Creatinine (μmol/L) 89.3 ± 35.6* N/A
*Expressed as mean ± standard deviation.
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proliferation with the presence of IgA as the sole or
predominant immunoglobulin deposition in mesangial area
of glomeruli. Patients had never received corticosteroids or
other immunosuppressive therapy. Patients with systemic
diseases such as Schonlein–Henoch purpura, rheumatoid
arthritis, diabetes mellitus or liver cirrhosis were excluded.
Ten age and sex matched healthy volunteers were selected
as normal controls. Measurements of blood pressure (BP),
urine routine and serum creatinine were performed to ex-
clude those who had abnormal findings. All of the patients
and healthy controls were from Chinese Han nationality.
This study was approved by the ethics committee of
West China Hospital of Sichuan University according to
the Declaration of Helsinki. Written informed consent
approved by the ethics committee was collected from
every subject involved in this study. This study is registered
as TCTR20140515001 in (Registration Date: 2014-05-15)
Thai clinical trial center.
Drugs
Astragalus membranaceus injection (AMI) was produced
by Chengdu Diao Pharmaceutical Company (1 ml AMI is
equivalent to 2 g crude drug) and diluted with RPMI 1640
medium to 2 g/ml. LPS was purchased from Sigma
Company, which was dissolved in RPMI 1640 medium to
500 μg/ml. AMI solution and LPS solution stored at 4°C
for later cell culture.
Lymphocyte isolation
Lymphocytes were obtained following a previously reported
method [6]. Briefly, 20 ml venous blood sample was
collected in EDTA anticoagulated tubes. Peripheral
blood mononuclear cells (PBMCs) were separated by
density gradient centrifugation using Lymphocyte-H
lymphocyte isolation media (Cedarlane Laboratories
Limited, Canada). PBMCs were washed 3 times with
Phosphate Buffered Saline (PBS, Sigma, USA) and resus-
pended in PBS + 2% Fetal bovine serum (FCS, GIBCO,
USA). Peripheral B lymphocytes were then isolated using
EasySep Human CD19 Selection Kit magnetic beads
(Stem cell, USA) according to manufacturer’s protocol.
The purity of B lymphocyte was greater than 95% by by
flow cytometry analysis (BD Bioscience, USA). Freshly
isolated B lymphocyte of each sample was resuspended
in RPMI-1640 medium (107cells/ml, Gibco, USA). Cell
morphology was monitored using a phase contrastmicroscope and cell viability was detected by trypan blue
dye staining which showed that cell activation > 95%.
Lymphocyte culture and treatment
Isolated B Lymphocytes were cultured (104 cells/ml)
with complete RPMI-1640 medium containing 15% fetal
calf serum+ L-glutamine 2 mM, HEPES 1 mM, penicillin
100 U/mL, streptomycin 100 mg/mL in 24-well plates at
37°C. Lymphocytes were divided into four groups: Group A
(Baseline): Baseline; Group B (LPS): RPMI + LPS; and
Group C (Low AMI): RPMI + LPS + Low dose AMI;
Group D: (High AMI): RPMI + LPS + High dose AMI.
The concentration of LPS was 12.5 μg/mL. Low and
High dose AMI were 200 mg/mL and 1000 mg/mL,
respectively. Cells were cultured in 24-well plates at
37°C for 3 days. Viability of B lymphocytes was about
85% as determined by trypan blue.
IgA1 ELISA analysis and Vicia villosa lectin-binding assay
IgA1 concentration of cell culture supernatants were
determined by ELISA [7]. As previously described, 96-well
plates were coated with primary antibody (Southern
Biotechnology Associates, USA) overnight at 4°C. After
blocking, samples were added in duplicate and incubated
for 1 h at 37°C with biotinylated secondary antibody
(Southern Biotechnology Associates, USA) and peroxidase-
avidin D (Vector Laboratories, UK), separately. Thereafter,
color was developed using tetramethyl benzidine dilu-
tion (TMB) and detected at 450 nm. Standard curve
constructed with a serial dilution of IgA1 standard serum
(Nordic Immunological Laboratories, Netherlands) was
used to calculate IgA1 concentration. The levels of IgA1
O-glycosylation were determined by Vicia villosa (VV)
lectin-binding assay. Briefly, samples were added in dupli-
cate to 96-well plates coated with primary antibody and
Figure 1 IgA1 (ng/mL) concentration in supernatant from IgAN patients and normal controls peripheral B lymphocytes. After LPS
stimulation, IgA1 was remarkably increased, especially in IgAN group. Treatment with AMI could inhibit the secretion of IgA1.
Table 3 IgA1 concentration (ng/mL) in IgAN patients and
normal controls
IgAN (n = 21) Normal controls (n = 10)
Baseline 326.04 ± 71.44a,b 150.73 ± 17.78a
LPS 573.86 ± 73.84b,c,d 322.89 ± 30.32d
LPS + AMI (Low) 376.12 ± 69.94 255.93 ± 33.64
LPS + AMI (High) 295.51 ± 61.75c 241.14 ± 42.68
a,b,c,dcomparison between 2 groups p < 0.05.
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UK) at 37°C and peroxidase-avidin D (Vector Laboratories),
color was developed and detected as above.
Cosmc gene qPCR quantification
Total RNA was extracted from lymphocytes using the
RNeasy Mini kit (QIAGEN, USA). Real-time quantitative
PCR (RT-PCR) was performed with the Taqman probe tech-
nique after reverse transcription. The primers and probes of
Cosmc and GAPDH (internal control) are listed in Table 1
(synthesized by Invitrogen, China). The PCR reaction was
performed in a Roche Lightcycler (Roche Diagnostics, USA)
as previously described. In order to examine the efficiency
of RT-PCR, standard curves were established with serial
dilutions of sample RNA (500 ng; 10 × dilution). PCR prod-
ucts were purified and sequenced directly (Invitrogen,
China). The sequencing result showed that the amplified
fragment was in accordance with the GenBank record.
Cosmc protein quantification
Cosmc protein quantification was performed using
Western blot as previously reported [8]. Protein samples of
lymphocytes were separated on 10% SDS PAGE gels and
transferred to PVDF membranes. After blocking, blots
were incubated with primary antibodies (1:200; Santa
Cruz Biotechnology, USA) overnight at 4°C and then with
horseradish peroxidase-linked secondary antibodies (1:5000;
Santa Cruz Biotechnology, USA). After further washing,
the immunoreactivities of antibodies were detected via
ECL reagents (GE Healthcare, USA). The measurement of
GAPDH was applied as an internal calibrator. OD
ratio of Cosmc/GAPDH was measured and analyzed
using Image-J software.Statistical analysis
Student t-test analyses were performed to evaluate the
changes in IgA1 and VV lectin binding levels. Delta Ct
was used in the analysis of Cosmc mRNA qPCR analysis.
P-value of 0.05 was taken as the level of statistical
significance. Pfaffl’s method, the most accepted method of
qPCR analysis, was applied during the analysis of
real-time PCR results.
Results
General features of subjects included
The clinical characteristics of the subjects are shown
in Table 2. Measurements of BP, urine routine, serum
creatinine, 24 hour urinary protein quantification were
performed in all patients. No significant difference was
observed in the age, sex and ethnological background of
IgAN patients and normal controls included (P > 0.05).
Effects of AMI on peripheral B lymphocyte IgA1 secretion
In cultured B lymphocyte from IgAN patients, IgA1
concentration in culture medium increased to a dramatic-
ally higher level than in normal controls after treatment of
LPS. However, Astragalus membranaceus injection (AMI)
Figure 2 IgA1 O-glycosylation assay in supernatant of IgAN patients and normal controls peripheral B lymphocytes.
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dose related inhibitory effect of AMI on IgA1 secretion
was observed. No significant effect of AMI on IgA1 secre-
tion in normal controls was observed (Figure 1, Table 3).Effects of AMI on peripheral B lymphocyte IgA1
glycosylation
Baseline serum VV lectin binding level of IgAN patient
was significantly higher than that of normal control,
indicating a higher aberrant glycosylation level. After
LPS stimulation, the VV lectin binding level dramatically
increased. Adding of AMI could reverse the increase of
VV lectin binding level, which indication an improvement
of dys-glycosylation level of IgA1 secreted by cultured B
lymphocytes of IgAN patients (Figure 2, Table 4).Effects of AMI on Cosmc gene expression
The baseline Cosmc mRNA expression level in peripheral B
lymphocytes of IgAN patients was significantly lower than
that of normal controls. Co-culture with LPS decreased the
Cosmc mRNA expression dramatically. Addition of AMI
could increase the mRNA expression of Cosmc gene appar-
ently in a dose related manner. (Figure 3, Table 5). Western
blot was applied to measure the Cosmc protein expressionTable 4 IgA1 VV lectin binding level in IgAN patients and
normal controls
IgAN (n = 21) Normal controls (n = 10)
Baseline 0.41 ± 0.02a,d 0.32 ± 0.03d
LPS 0.52 ± 0.03a,b,c,e 0.35 ± 0.03e
LPS + AMI (Low) 0.44 ± 0.03b 0.34 ± 0.03
LPS + AMI (High) 0.44 ± 0.02c 0.34 ± 0.02
a,b,c,d,ecomparison between 2 groups p < 0.05.levels in each group, which indicated a result in accordance
with that of qPCR results (Figure 4).
Discussion
IgAN is the most common glomerulonephritis in Asian
countries. Hinge region dys-glycosylation of IgA1 molecule
is considered as one of the key pathogenesis of IgAN. It
was reported that sera, mesangial deposited and tonsil
secreted IgA1 molecules in IgAN were significantly low in
O-glycan level [9,10]. In previous studies we found that the
specific functional chaperon of β1,3-galactosyltransferases,
which participates in the glycosylation process of
IgA1, is remarkably lower in peripheral B lymphocyte
of IgAN patients [3,6]. Moreover, reverse of Cosmc
gene expression might be the potential mechanism of
mycophenolic acid in treating IgAN [7,8].
Astragalus mongholicus (AM) derived from the dry root
of Astragalus membranaceus, which belongs to leguminous
plant of the Astragalus family, is one of the most popular
traditional Chinese medicines. AM is composed of glyco-
side, astragalus polysaccharides, multi-amino acids, astrag-
alus total saponin, caritinoid, astragalus total flavonoids,
and microelement. It has been widely used in China and
East Asia area for many years to treat myocardial ischemia,
liver fibrosis, chronic nephritis, diabetes, etc. [4,11]. It has
been shown to have several biological properties: antioxi-
dant, antiaging, antiviral and inhibiting intracellular calcium
overload. AM has been shown to possess renoprotective
activity by attenuating glomerular sclerotic injury in
experimental diabetic nephropathy. Previously, we found
that AM could significantly inhibit the renal fibrosis by
up-regulating hepatocyte growth factor (HGF) and down-
regulating transforming growth factor-β1 (TGF-β1) [12].
Further study indicated that AM could lower the level of
hematuria, 24 hours-albuminuria and urine NAG of the
Figure 3 The expression levels of Cosmc mRNA represented by Delta Ct.
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pathology and reduce the deposit of IgA in glomerular
mesangium [5]. Down-regulation of NF-kappaB and
MCP-1 expression in kidney as well as regulate the
balance of Th1 and Th2 cells was considered as the
potential mechanism of AMI in treating IgAN [13,14].
However, no study has been done to clarify the effect of
AMI on dys-glycosylation of IgA1 in IgAN patients.
In the current study, we found that peripheral B
lymphocytes from IgAN patients secreted apparently
higher level of IgA1 compared with normal controls at
baseline and under LPS stimulation. VV lectin binding
assay indicated significant aberrant IgA1 O-glycosylation
in IgAN patients. qPCR shown deficiency of Cosmc gene
expression in IgAN patients. These data were in accordance
with our previous findings [3,6].
Previously, we found that reverse of Cosmc expression
was a potential method of treating IgAN. It was found that
up-regulation of Cosmc expression by 5-AZA and MPA
could reverse the IgA1 dys-gylcosylation level significantly
[7,8]. In this study, we found that treatment with
AMI could dramatically inhibit the secretion of IgA1
induced by LPS stimulation in peripheral B lymphocytesTable 5 Cosmc mRNA level in IgAN patients and normal
controls
IgAN (n = 21) Normal controls (n = 10)
Baseline 0.035 ± 0.005a,e,f 0.059 ± 0.013f
LPS 0.023 ± 0.003a,b,c,d,g 0.052 ± 0.011g
LPS + AMI (Low) 0.055 ± 0.015b 0.058 ± 0.024
LPS + AMI (High) 0.103 ± 0.018c,d,e 0.061 ± 0.025
a,b,c,d,e,f,gcomparison between 2 groups p < 0.05.from IgAN patients (573.86 ± 73.84 vs 376.12 ± 69.94 vs
295.51 ± 61.75, p < 0.05). Meanwhile, the expression levels
of Cosmc increased signicantly after addition of AMI in a
dose dependent manner (0.023 ± 0.003 vs 0.055 ± 0.015 vs
0.103 ± 0.018, p < 0.05). These changes indicated an appar-
ently improvement of O-glycosylation in IgA1 secreted
from isolated peripheral B lymphocytes (0.52 ± 0.03 vs
0.44 ± 0.03 vs 0.44 ± 0.02, p < 0.05). These results sug-
gested that, reverse of Cosmc gene expression and im-
prove of IgA1 O-glycosylation level might be the theoretic
mechanism of AMI in the treatment of IgAN patients.
Currently, IgA nephropathy was mainly treated with
RAS inhibitors, corticosteroids and immunosuppressant,
which is not specific and sometimes ineffective [15].
Immunosuppressant treatment sometimes even cause se-
vere side effect such as life-threating infection. Moreover,
the anti-hypertensive effect of RAS inhibitors limited its
uses in patients with normal blood pressure. Astagalus
membranaceus, as a widely used immunomodulating herb
in traditional Chinese medicine, has been recognized as a
helpful complementary therapy of IgAN. Our current
study provided new evidence of AM in the treatment of
IgAN patients. However, further random control trials
should be carried out to verify the in vitro results in IgAN
patients.
Conclusion
In summary, for the first time, our data demonstrates that
Astagalus membranaceus injection could up-regulate
cosmc gene expression and improve IgA1 O-glycosylation
level of peripheral B lymphocyte from IgAN in vitro,
which may be the potential mechanism of its therapeutic
effect in IgAN.
Figure 4 Western blot analysis for Cosmc protein after cultured in presence or absence of LPS and AMI.
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